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INTRODUCTION
A variety of chromosomal alterations, such as translocation,
deletion or mutation, play an important role in the pathogen-
esis of many human hematologic malignancies (1-3), and the
detection of proteins encoded by altered chromosomes has
been used in diagnosis of hematologic disorders (4).
Pax5 gene is a member of the paired-box Pax gene family,
and encodes the transcription factor, Pax5, and is also known
as B-cell-specific activator protein (BSAP) which is detected
in the developing central nervous system, in the adult testis,
and in the cells of the B-lymphoid lineage (5). In B cell devel-
opment, Pax5 gene transcription is initiated in pro-B (pre-BI)
cell stage, and expressed through the pre-B- and mature B
cells, but not in plasma cells (5, 6). It activates expression of
mb-1, LEF-1, N-myc, and also the CD19 gene (5, 7, 8). About
half of the lymphoplasmacytic lymphomas are associated with
t(9;14) (p13;q32), which leads to juxtaposition of Pax5 gene
to IgH gene (3, 9, 10). Recently, polyclonal and monoclonal
antibodies for Pax5 protein were used in routinely processed
lymphoid neoplasia and reported to be an excellent pan-B and
pan-pre-B cell marker, which are not associated with chromo-
somal alterations (11, 12).
In this study, the expression of Pax5 was immunohistochem-
ically detected in non-Hodgkin’s lymphomas and in leukemias
to evaluate its usefulness as B cell marker.
MATERIALS AND METHODS
Materials
Non-Hodgkin’s lymphomas and acute leukemias were se-
lected from the Pathology File in the Department of Pathol-
ogy, Anam Hospital of Korea University Medical College,
Seoul, Korea. The tissues were routinely processed with 10%
buffered formalin fixation and paraffin embedding. The diag-
nosis and classification of lymphomas were dependent upon
the routine H-E stained slides and immunohistochemistry.
The diagnosis was supplemented by IgH and TCR rearrange-
ment studies and followed the WHO classification. In leu-
kemias, the immunophenotyping was performed by flow
cytometry, using a panel of monoclonal antibodies, and bone
marrow core biopsies were used for this study. All slides were
reviewed, and appropriate areas were marked and selected for
the tissue microarray. Agar blocks for tissue microarray were
prepared as follows. Agar (4 g) was dissolved into 100 mL
distilled water and boiled in microwave for 2 min; it was solid-
ified in the cast, and was routinely processed as tissue sample;
the agar was embedded in paraffin; the selected area of the
each case was punch-holed using skin punch biopsy tool (2
mm in diameter) and was transplanted into the agar block,
which was also punch-holed with the same biopsy tool; and
after all cases were re-embedded into the agar block, the block
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Pax5 expression in Non-Hodgkin’ s Lymphomas and Acute Leukemias
The Pax5 gene encodes the B-cell-specific activator protein which is a key regula-
tor in development and differentiation of B-cell. We studied the expression of Pax5
in hematologic malignancies to evaluate the diagnostic utility as a B cell marker.
Materials included 70 B cell lymphomas, 26 T cell lymphomas, 53 acute leuke-
mias, and 6 multiple myelomas (MMs). Representative areas from the paraffin-
embedded tissues were selected for tissue microarray, and the expressions of
Pax5 was immunohistochemically evaluated. Pax5 was strongly expressed in most
of the B cell lymphomas; 44 of 47 diffuse large B cell lymphomas (93.6%), 15 of
16 marginal zone B cell lymphomas (93.8%), all 3 mantle cell lymphomas, 2 follic-
ular lymphomas, and 2 Burkitt’s lymphomas (100%). However, Pax5 was express-
ed in only one of 26 T cell lymphomas. Among leukemias, it was expressed in 10
of the 14 B acute lymphocytic leukemias (ALLs) (72.4%), but also in 3 of the 6 T
ALLs (50%), 13 of the 26 acute myelogenous leukemias (AMLs) (50%) and in all
3 ALL arising in chronic myelogenous leukemias and 4 mixed B ALL and AML. In
MMs, Pax5 was negative in all cases. We concluded that Pax5 is very useful B
cell marker in classification of lymphomas, but not of acute leukemias. 
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was incubated at 37℃ for 30 min to mould the tissues into
paraffin.
The selected cases included 53 acute leukemias (14 B acute
lymphocytic leukemias [ALLs], 6 T ALLs, 26 acute myeloge-
nous leukemias [AMLs], 3 ALLs arising in chronic myeloge-
nous leukemia [CML], and 4 mixed B ALL and AML), 70 B
cell lymphomas (47 diffuse large B cell lymphomas [DLBCL],
16 marginal zone B cell lymphomas [MZBCL], 2 follicular
lymphomas [FL], 2 Burkitt’s lymphomas [BL], and 3 mantle
cell lymphomas [MCL]), 26 T cell lymphomas (9 not other-
wise specified [NOS], 6 NK/T cell lymphomas [NK/T], 3
angioimmunoblastic lymphomas [AIL], 3 anaplastic lym-
phomas [AL], and 5 lymphoblastic [LB]). Six cases of multi-
ple myeloma [MM] were also included.
Immunohistochemical Staining
For immunohistochemical staining, 4- m thick section
from microarray blocks were deparaffinized and rehydrated.
After endogenous peroxidase activity was eliminated by incu-
bation with 3% H2O2 in methanol, the retrieval of antigen
was done by placing the slides for 2 min in a pressure cooker
(103 Kpa) containing 0.01 M sodium citrate buffer (pH 6.0).
The slides were then incubated with the primary monoclonal
antibodies, Pax5 (1:50, Transduction Laboratories, Lexington,
KY, U.S.A.) for one hour at room temperature. After incubat-
ing for 30 min with biotinylated link antibody, the sections
were re-incubated with streptavidin-peroxidase complex for
30 min. Immunostaining was visualized by using 3, 3′di-
aminobenzidine. The sections were counterstained with hema-
toxylin. As a negative control, 0.1 M Tris buffer (pH 7.6) re-
placed the primary antibody, and the tonsil and lymph node
were used as positive control.
Immunohistochemical result for Pax5 protein was interpret-
ed as positive, when the nucleus of neoplastic cells was positive.
RESULTS
Pax5 expression was in the nuclei of B lymphocytes of nor-
mal tonsil and lymph node. The germinal center cells were
found positive, but mantle cells were the strongest. T zone
lymphocytes, plasma cells, endothelial cells, and macrophages
were found negative. In B cell lymphomas, all BLs (2/2), MCLs
(3/3) and FLs (2/2), 44 of 47 DLBCLs (93.6%) and 15 of 16
MZBCLs (93.8%) were found positive. The nuclear staining
in B cell lymphomas was diffusely strong in most of the neo-
plastic cells, whereas the staining was patch, mainly in the
nuclei of the small lymphocytes and centrocyte-like cells, but
not in plasma cells in MZBCLs. Six MMs were found entirely
negative. Pax5 was found negative in all T cell lymphomas
except in one of the 5 LBs (20%). In LBs, the positive cells
were found in less than 50% of the neoplastic cells. Pax5 was
expressed in 10 of the 14 B ALLs (72.4%), 3 of 6 T ALLs
(50%), 13 of 26 AMLs (50%), and in all 3 ALLs arising in
CML and 4 mixed B ALL and AML (100%).
DISCUSSION
Pax5 protein is known to be a B-cell specific marker, which
is expressed exclusively in normal and neoplastic B cells. The
levels of Pax5 expression varied among different B cell subsets
and among B cell NHL subtypes. In normal lymphoid tissues,
Pax5 expression was found in B lymphocytes, but not in plas-
ma cells (5, 6, 13 ). In our study, Pax5 expression was mainly
seen in the nuclei of B cell follicles, and mantle cells of normal
tonsil and lymph node were strong, but T zone lymphocytes,
plasma cells, endothelial cells, and macrophages were found
negative. Among B cell lymphomas, strong expression of
Pax5 was seen in most of MCL, DLBCL, FL, BL, and MZBCL.
Interestingly, the staining in MZBCL was patch and was main-
ly limited in the nuclei of the small lymphocytes and centro-
cyte-like cells, but not in plasma cells. The study done by
Foss et al. (14) showed that all B cell lymphomas were found
positive for Pax5, whereas all T cell lymphomas were found
negative, though two of the 5 plasmacytomas showed a focal
positive reaction by in situ hybridization. The results of the
studies of Krenacs et al. (11) and Torlakovic et al. (12), which
included a relatively large numbers of a variety of histologic
subtypes, showed similar results. However, in our study, Pax5
was expressed in one T cell LB lymphoma, 3 of 6 T ALLs, and
13 of 26 AMLs. The expression of Pax5 was not related with
CD19 expression, which was studied in flow cytometry. Our
DLBCL, Diffuse large B cell lymphoma; MZBCL, Marginal zone B cell lym-
phoma; FL, Follicular lymphoma; MCL, Mantle cell lymphoma; MM, Multi-
ple myeloma; NOS, Not otherwise specified; AIL, Angioimmunoblastic.
Diagnosis
Total
Cases
No. of Positive
Cases (%)
B cell neoplasm DLBCL 47 44 (93.6)
MZBCL 16 15 (93.8)
FL 2 2 (100)
Lymphoblastic 2 2 (100)
MCL 3 3 (100)
MM 6 0 (0)
T cell neoplasm NOS 9 0 (0)
NK/T 6 0 (0)
AIL 3 0 (0)
Anaplastic 3 0 (0)
Lymphoblastic 5 1  (20)
Leukemia Early PreB ALL 7 5 (72.4)
PreB ALL 7 5 (72.4)
ALL in CML 3 3 (100)
T ALL  6 3 (50)
AML 26 13 (50)
Mixed B ALL and AML 4 4 (100)
Table 1. Expression of Pax5 in Non-Hodgkin’s Lymphomas and
Leukemias806 X. Zhang, Z. Lin, I. Kim
result on leukemias could not be compared with other results
because there were no studies available readily. Pax5 is impor-
tant for maintaining the identity and the functions of mature
B cells in late B-lymphopoiesis, as well as its transcriptional
program in early development of B-cell (5-7, 15, 16). The loss
of Pax5 leads to reverse B-lineage commitment by convert-
ing pro-B cells into hematopoietic progenitors with a broad
potential in development (7, 17, 18). Pax5 can be ectopically
expressed in a multipotent hematopoietic cell line (18). The
expression of Pax5 in hematopoietic progenitor had minimal
effects on myeloid differentiation, suggesting that Pax5 is un-
able to repress myeloid gene transcription in the circumstance
of abundant myeloid transcription factors (19). This may ex-
plain the expression of Pax5 in AML and T ALL of our stud-
ies. Pax5 is also reported to be expressed in Reed-Sternberg
and Hodgkin’s cells in classic and lymphocyte predominance
Hodgkin’s lymphomas (11, 12, 20). Recently, Willenbrock
et al. (21) presented a case of classic Hodgkin’s lymphoma, in
which the tumor cells showed clonal rearrangement of T cell
receptor  gene, as well as aberrant expression of Pax5 in
CD30
+and CD15
+tumor cells. All these findings may explain
the expression of Pax5 in the case of T LB lymphoma and of
Fig. 1. (A) Germinal center and mantle zone cells are strongly positive for Pax5 in the normal tonsil (×200). (B) In MZBCL, the staining was
patch and was mainly in the nuclei of the small lymphocytes (×100). (C) The nodules of FL are positive for Pax5 (×100). (D) DLBCL is dif-
fusely strong positive for Pax5 (×100). (Fig.1 continued next)
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myeloid leukemias of our study.
In summary, our results showed that Pax5 can be used as
a valuable diagnostic marker of B cell lymphomas and of acute
lymphoblastic leukemia; however, it has limited value in clas-
sification of acute leukemias.
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